Previous studies have demonstrated the ability of TDO2 inhibitors to inhibit lung metastasis in BC.[38] Moreover, we identified several potential therapies for the low-risk group including cyclopamine, cytarabine, dasatinib, bexarotene, and dimethyloxallyl glycine. This evidence concerns the gene TDO2 and breast cancer.